Effectivity of Lumbrokinase in Reducing Proteinuria on patients with Diabetic Kidney Disease

Background: Diabetes Mellitus (DM) is currently developing epidemically and diabetic kidney disease is a major complications affecting one-third of patients with DM. Lumbrokinase is an extract from a worm belonging to the class Lumbricus rubellus, containing bioactive proteolytic enzymes, which is considered as an alternative therapy in reducing proteinuria. Aim: This study aims analysing the effect of the administration of Lumbrokinase in reduction of proteinuria in patients with diabetic kidney disease. Materials & Methods: The study design is a prospective observational study in 6 type 2 DM patients with diabetic kidney disease characterised by proteinuria in RSPAD Gatoto Soebroto, Jakarat, Indonesia. The patients were administered with Lumbrokinase 250mg with a dose of 3x2 capsules daily for 12 weeks. Observations: Study shows no significant difference between laboratory parameters before and after Lumbrokinase administration. However, proteinuria seems to improve, which is marked with decreased Urinary Albumin Creatinine Ratio (UACR) level after Lumbrokinase administration Conclusion: Lumbrokinase appears to be able to decrease proteinuria in type 2 DM patients with diabetic kidney disease. However, further research with more samples is needed.